Simponi Maintains Long-Term Effects in UC Patients, GO-COLITIS Results Show

Simponi Maintains Long-Term Effects in UC Patients, GO-COLITIS Results Show
Results from the GO-COLITIS clinical trial (NCT02092285) confirm that the long-term effects of Janssen Pharmaceutical’s Simponi (golimumab) were maintained in patients with ulcerative colitis (UC), according to MSD, sponsor of the study. The United Kingdom (UK)-based study confirmed the effectiveness of the drug in inducing and maintaining clinical response during the 66 weeks of treatment since the beginning of the trial. “We are encouraged by the proportion of patients who maintained clinical response up to and beyond one year, and what this means to patients in terms of disease control,” Chris Probert, MD, lead study investigator, said  in a press release. Probert is a professor at the University of
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *